Yanjie You1,2,3, Haijun Li4, Xin Qin5, Yonggang Ran6, Fei Wang7,8. 1. Pathological Examination and Research Center, Luohe Medical College, Luohe, 462002, China. 2. Department of Pharmacy, Luohe Medical College, Luohe, 462002, China. 3. Luohe Key Laboratory of Medical Bioengineering, Luohe Medical College, 148 Daxue-Road, Luohe, 462002, China. 4. Department of Radiation Oncology, The Second People's Hospital of Neijiang City, Neijiang, 641000, China. 5. Medical College, Hubei University of Arts and Science, Xiangyang, 441053, China. 6. Department of Teaching and Training, Bethune Military Medical NCO Academy of PLA, Shijiazhuang, 050081, China. 7. Luohe Key Laboratory of Medical Bioengineering, Luohe Medical College, 148 Daxue-Road, Luohe, 462002, China. whovering@yahoo.com. 8. Bioengineering Laboratory, Luohe Medical College, Luohe, 462002, China. whovering@yahoo.com.
Abstract
BACKGROUND: Recently, we identified the esophageal carcinoma related gene 4 (ECRG4) as a novel candidate tumor suppressor gene and a promising therapeutic target in nasopharyngeal carcinoma (NPC). In addition, we found that reduced ECRG4 expression in NPC was associated with promoter hypermethylation. The aim of the current study was to assess the expression status of the ECRG4 protein in breast cancer and to clarify its clinicopathological significance and potential prognostic implications. METHODS: Western blotting was used to examine ECRG4 protein levels in 20 paired breast cancer tissues and adjacent noncancerous tissues. In addition, we performed ECRG4 immunohistochemistry on 113 clinicopathologically well-characterized breast cancer samples and assessed putative associations between its expression and overall patient survival rates. RESULTS: We found that ECRG4 protein expression was significantly reduced in the breast cancer tissues compared to the noncancerous tissues. Clinicopathological analyses revealed that loss of ECRG4 protein expression, observed in 41.6 % (47/113) of the primary breast cancer tissues tested, was significantly correlated with lymph node metastasis (P = 0.026), advanced tumor stage (P = 0.042) and unfavorable overall survival (P = 0.004). Additional multivariate analyses revealed that ECRG4 protein expression may serve as an independent prognostic factor for the prediction of patient survival (P = 0.033). CONCLUSION: Our data suggest that loss of ECRG4 protein expression may be involved in tumor progression and may serve as a prognostic biomarker for breast cancer.
BACKGROUND: Recently, we identified the esophageal carcinoma related gene 4 (ECRG4) as a novel candidate tumor suppressor gene and a promising therapeutic target in nasopharyngeal carcinoma (NPC). In addition, we found that reduced ECRG4 expression in NPC was associated with promoter hypermethylation. The aim of the current study was to assess the expression status of the ECRG4 protein in breast cancer and to clarify its clinicopathological significance and potential prognostic implications. METHODS: Western blotting was used to examine ECRG4 protein levels in 20 paired breast cancer tissues and adjacent noncancerous tissues. In addition, we performed ECRG4 immunohistochemistry on 113 clinicopathologically well-characterized breast cancer samples and assessed putative associations between its expression and overall patient survival rates. RESULTS: We found that ECRG4 protein expression was significantly reduced in the breast cancer tissues compared to the noncancerous tissues. Clinicopathological analyses revealed that loss of ECRG4 protein expression, observed in 41.6 % (47/113) of the primary breast cancer tissues tested, was significantly correlated with lymph node metastasis (P = 0.026), advanced tumor stage (P = 0.042) and unfavorable overall survival (P = 0.004). Additional multivariate analyses revealed that ECRG4 protein expression may serve as an independent prognostic factor for the prediction of patient survival (P = 0.033). CONCLUSION: Our data suggest that loss of ECRG4 protein expression may be involved in tumor progression and may serve as a prognostic biomarker for breast cancer.
Entities:
Keywords:
Breast cancer; ECRG4; Immunohistochemistry; Prognosis
Authors: Damián E Berardi; Carolina Flumian; Paola B Campodónico; Alejandro J Urtreger; María I Diaz Bessone; Andrea N Motter; Elisa D Bal de Kier Joffé; Eduardo F Farias; Laura B Todaro Journal: Cell Oncol (Dordr) Date: 2015-06-05 Impact factor: 6.730
Authors: Ana Maria Gonzalez; Sonia Podvin; Shuh-Yow Lin; Miles C Miller; Hannah Botfield; Wendy E Leadbeater; Andrew Roberton; Xitong Dang; Stuart E Knowling; Elena Cardenas-Galindo; John E Donahue; Edward G Stopa; Conrad E Johanson; Raul Coimbra; Brian P Eliceiri; Andrew Baird Journal: Fluids Barriers CNS Date: 2011-01-18
Authors: Robert A Dorschner; Jisook Lee; Olga Cohen; Todd Costantini; Andrew Baird; Brian P Eliceiri Journal: Sci Adv Date: 2020-03-11 Impact factor: 14.957